Thomas Secher

Publications

Article dans une revue (45)

Excipients in orally inhaled protein formulations: Current examples, challenges, and future directions Bhupinder Kaur,Thomas Sécher,Nathalie Heuzé-Vourc’h Drug Discovery Today, 2026, pp.104642. ⟨10.1016/j.drudis.2026.104642⟩ Article dans une revue hal-05559679v1
Pseudopaline-mediated zinc uptake by Pseudomonas aeruginosa drives clinically relevant phenotypes and infection outcomes Lola Bosc,Thomas Sécher,Genevieve Ball,Deborah Le Pennec,Mathilde Triboutet al. Infection and Immunity, 2026, 94 (2), pp.e00453-25. ⟨10.1128/iai.00453-25⟩ Article dans une revue hal-05458347v1
Exploring airway biological barriers: Implications for IgG-based therapeutics in respiratory infections Gabrielle Pichon,Christelle Parent,Stefanie Graeter,Alexander Schaub,Anna Schnellet al. European Journal of Pharmaceutics and Biopharmaceutics, 2025, 215, pp.114817. ⟨10.1016/j.ejpb.2025.114817⟩ Article dans une revue hal-05241299v1
A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview Noémie Alphonse,Thomas Secher,Nathalie Heuzé-Vourc’h Expert Opinion on Drug Delivery, 2025, 22 (2), pp.197-218. ⟨10.1080/17425247.2024.2446608⟩ Article dans une revue hal-04976146v1
Synergy between Lactobacillus murinus and anti-PcrV antibody delivered in the airways to boost protection against Pseudomonas aeruginosa Thomas Secher,Mélanie Cortes,Chloé Boisseau,Marie-Thérèse Barba Goudiaby,Aubin Pitiotet al. Molecular Therapy - Methods and Clinical Development, 2024, 32 (4), pp.101330. ⟨10.1016/j.omtm.2024.101330⟩ Article dans une revue hal-04834283v1
The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies Timothée Blin,Christelle Parent,Gabrielle Pichon,Antoine Guillon,Youenn Jouanet al. European Journal of Pharmaceutics and Biopharmaceutics, 2024, 195, pp.114163. ⟨10.1016/j.ejpb.2023.12.003⟩ Article dans une revue hal-04484465v1
Barriers for orally inhaled therapeutic antibodies Thomas Secher,Nathalie Heuzé-Vourc’h Expert Opinion on Drug Delivery, 2023, 20 (8), pp.1071-1084. ⟨10.1080/17425247.2023.2249821⟩ Article dans une revue hal-04834313v1
Aggregates Associated with Instability of Antibodies during Aerosolization Induce Adverse Immunological Effects Thomas Sécher,Elsa Bodier-Montagutelli,Christelle Parent,Laura Bouvart,Mélanie Corteset al. Pharmaceutics, 2022, 14 (3), pp.671. ⟨10.3390/pharmaceutics14030671⟩ Article dans une revue hal-03687448v1
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives Alexie Mayor,Adélaïde Chesnay,Guillaume Desoubeaux,David Ternant,Nathalie Heuzé-Vourc'Het al. Vaccines, 2021, 9 (2), pp.151. ⟨10.3390/vaccines9020151⟩ Article dans une revue hal-03485350v1
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States Marion Ferreira,Thomas Secher,Nathalie Heuzé-Vourc'H,Karen Reckamp Pharmaceutics, 2021, 13 (6), pp.912. ⟨10.3390/pharmaceutics13060912⟩ Article dans une revue hal-03382451v1
Chronic Pseudomonas aeruginosa Lung Infection Is IL-1R Independent, but Relies on MyD88 Signaling Claire Mackowiak,Tiffany Marchiol,Hana Cipcic Paljetak,Louis Fauconnier,Jennifer Palomoet al. ImmunoHorizons , 2021, 5 (5), pp.273-283. ⟨10.4049/immunohorizons.2000095⟩ Article dans une revue hal-03258180v1
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them Yara Al Ojaimi,Timothée Blin,Juliette Lamamy,Matthieu Gracia,Aubin Pitiotet al. Pharmacology & Therapeutics, 2021, pp.108022. ⟨10.1016/j.pharmthera.2021.108022⟩ Article dans une revue hal-03531953v1
MAIT Cells Display a Specific Response to Type 1 IFN Underlying the Adjuvant Effect of TLR7/8 Ligands Marion Pavlovic,Christelle Gross,Chahinaize Chili,Thomas Secher,Emmanuel Treiner Frontiers in Immunology, 2020, 11 (article 2097), pp.1-16. ⟨10.3389/fimmu.2020.02097⟩ Article dans une revue hal-03154944v1
Inhalation of Immuno-Therapeutics/- Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place! Thomas Secher,Alexie Mayor,Nathalie Heuzé-Vourc'H Frontiers in Immunology, 2019, 1, ⟨10.3389/fimmu.2019.02760⟩ Article dans une revue hal-02439828v1
The regenerating family member 3 β instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure Nadine Waldschmitt,Sho Kitamoto,Thomas Secher,Vassiliki Zacharioudaki,Olivier Boulardet al. Gut, 2019, 68 (7), pp.1190-1199. ⟨10.1136/gutjnl-2018-316757⟩ Article dans une revue hal-02126570v1
Deciphering the interplay between the genotoxic and probiotic activities of Escherichia coli Nissle 1917 Clémence Massip,Priscilla Branchu,Nadège Bossuet-Greif,Camille V Chagneau,Déborah Gaillardet al. PLoS Pathogens, 2019, 15 (9), pp.e1008029. ⟨10.1371/journal.ppat.1008029⟩ Article dans une revue inserm-02320208v1
In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration Thomas Secher,Emilie Dalonneau,Marion Ferreira,Christelle Parent,Nicolas Azzopardiet al. Journal of Controlled Release, 2019, 303, pp.24-33. ⟨10.1016/j.jconrel.2019.04.005⟩ Article dans une revue hal-02179896v1
The probiotic strain Escherichia coli Nissle 1917 prevents papain-induced respiratory barrier injury and severe allergic inflammation in mice Thomas Secher,Isabelle Maillet,Claire Mackowiak,Jessica Le Bérichel,Amandine Philippeauet al. Scientific Reports, 2018, 8 (1), ⟨10.1038/s41598-018-29689-9⟩ Article dans une revue hal-02126575v1
Therapeutic antibodies: A new era in the treatment of respiratory diseases? Thomas Secher,L. Guilleminault,K. Reckamp,I. Amanam,L. Plantieret al. Pharmacology & Therapeutics, 2018, 189, pp.149-172. ⟨10.1016/j.pharmthera.2018.05.003⟩ Article dans une revue istex hal-02439820v1
Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics A. Guillon,Thomas Secher,L.A. Dailey,L. Vecellio,M. de Monteet al. International Journal of Pharmaceutics, 2018, 536 (1), pp.116-126. ⟨10.1016/j.ijpharm.2017.11.049⟩ Article dans une revue hal-02439838v1
Mu and delta opioid receptor knockout mice show increased colonic sensitivity David Reiss,Rhian Alice Ceredig,Thomas Secher,J. Boué,Frédérick Barreauet al. European Journal of Pain, 2017, 21 (4), pp.623-634. ⟨10.1002/ejp.965⟩ Article dans une revue hal-01607491v1
The food contaminant deoxynivalenol exacerbates the genotoxicity of gut microbiota Delphine Payros,Ulrich Dobrindt,Patricia Martin-Bizon,Thomas Secher,Ana-Paula Loureiro-Bracarenseet al. mBio, 2017, 8 (2), 11 p. ⟨10.1128/mBio.00007-17⟩ Article dans une revue hal-01608529v1
Oral Administration of the Probiotic Strain &lt;em&gt;Escherichia coli&lt;/em&gt; Nissle 1917 Reduces Susceptibility to Neuroinflammation and Repairs Experimental Autoimmune Encephalomyelitis-Induced Intestinal Barrier Dysfunction Thomas Secher,Sahar Kassem,Mehdi Benamar,Isabelle Bernard-Cadenat,Michèle Bouryet al. Frontiers in Immunology, 2017, 8, ⟨10.3389/fimmu.2017.01096⟩ Article dans une revue hal-02624001v1
DNA Inversion Regulates Outer Membrane Vesicle Production in B&lt;em&gt;acteroides fragilis&lt;/em&gt; Haruyuki Nakayama-Imaohji,Katsuhiko Hirota,Hisashi Yamasaki,Saori Yoneda,Hirofumi Nariyaet al. PLoS ONE, 2016, 11 (2), pp.1-21. ⟨10.1371/journal.pone.0148887⟩ Article dans une revue hal-02632202v1
Early settlers: which E. coli strains do you not want at birth? Thomas Secher,Camille Brehin,Eric Oswald AJP - Gastrointestinal and Liver Physiology, 2016, 311 (1), pp.G123 - G129. ⟨10.1152/ajpgi.00091.2016⟩ Article dans une revue hal-01602829v1
Oral tolerance failure upon neonatal gut colonization with Escherichia coli producing the genotoxin colibactin Thomas Secher,Delphine Payros,Camille Brehin,Michèle Boury,Claude Watrinet al. Infection and Immunity, 2015, 83 (6), pp.2420-2429. ⟨10.1128/IAI.00064-15⟩ Article dans une revue hal-02634629v1
Retrograde trafficking inhibitor of Shiga toxins reduces morbidity and mortality of mice infected with enterohemorrhagic &lt;em&gt;Escherichia coli&lt;/em&gt; Thomas Secher,Ayaka Shima,Karen Hinsinger,Jean Christophe Cintrat,Ludger Johanneset al. Antimicrobial Agents and Chemotherapy, 2015, 59 (8), pp.5010-5013. ⟨10.1128/AAC.00455-15⟩ Article dans une revue hal-02640796v1
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice Rodrigo Guabiraba,Anne-Gaëlle Besnard,Gustavo Batista Menezes,Thomas Secher,M. S. Jabiret al. Mucosal Immunology, 2014, 7 (5), pp.1079-1093. ⟨10.1038/mi.2013.124⟩ Article dans une revue hal-02633989v1
Maternally acquired genotoxic Escherichia coli alters offspring's intestinal homeostasis Delphine Payros,Thomas Secher,Michèle Boury,Camille Brehin,Sandrine Ménardet al. Gut microbes, 2014, 5 (3), pp.313-325. ⟨10.4161/gmic.28932⟩ Article dans une revue hal-01859355v2
NOD2 prevents emergence of disease-predisposing microbiota Thomas Secher,Sylvain Normand,Mathias Chamaillard Gut microbes, 2013, 4 (4), pp.353-356. ⟨10.4161/gmic.25275⟩ Article dans une revue hal-02180087v1
Dysbiosis, a new medical concept Sylvain Normand,Thomas Secher,Mathias Chamaillard Médecine/Sciences, 2013, 29 (6-7), pp.586-589. ⟨10.1051/medsci/2013296011⟩ Article dans une revue hal-02180092v1
Blockade of IL-1R signaling diminishes Paneth cell depletion and Toxoplasma gondii induced ileitis in mice Bérengère Villeret,Lea Brault,Aurélie Couturier-Maillard,Pauline Robinet,Virginie Vasseuret al. American journal of Clinical and Experimental Immunology, 2013, 2 (1), pp.107-116 Article dans une revue hal-02651056v1
NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. Aurélie Couturier-Maillard,Thomas Secher,Ateequr Rehman,Sylvain Normand,Adèle de Arcangeliset al. Journal of Clinical Investigation, 2013, 123 (2), pp.700-11. ⟨10.1172/JCI62236⟩ Article dans une revue hal-00944194v1
&lt;em&gt;Escherichia coli&lt;/em&gt; producing colibactin triggers premature and transmissible senescence in mammalian cells Thomas Secher,Ascel Samba Louaka,Eric Oswald,Jean-Philippe Nougayrède PLoS ONE, 2013, 8 (10), ⟨10.1371/journal.pone.0077157⟩ Article dans une revue hal-02646496v1
Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity Maïwenn Olier,Ingrid Marcq,Christel Cartier,Thomas Secher,Ulrich Dobrindtet al. Gut microbes, 2012, 3 (6), pp.501-509. ⟨10.4161/gutmicrobes.21737⟩ Article dans une revue hal-02935516v1
Parasite-derived plasma microparticles contribute significantly to malaria infection-induced inflammation through potent macrophage stimulation. Kevin N Couper,Tom Barnes,Julius C R Hafalla,Valery Combes,Bernhard Ryffelet al. PLoS Pathogens, 2010, 6 (1), pp.e1000744. ⟨10.1371/journal.ppat.1000744⟩ Article dans une revue hal-00591502v1
Remote control of intestinal tumorigenesis by innate immunity. Thomas Secher,Olivier Gaillot,Bernhard Ryffel,Mathias Chamaillard Cancer Research, 2010, 70 (5), pp.1749-52. ⟨10.1158/0008-5472.CAN-09-3401⟩ Article dans une revue hal-00591500v1
Local and remote tissue injury upon intestinal ischemia and reperfusion depends on the TLR/MyD88 signaling pathway. Tatiana Victoni,Fernando Rodrigues Coelho,Alexandre Learth Soares,Andressa de Freitas,Thomas Secheret al. Medical Microbiology and Immunology, 2010, 199 (1), pp.35-42. ⟨10.1007/s00430-009-0134-5⟩ Article dans une revue istex hal-00591521v1
IL-17 receptor signaling is required to control polymicrobial sepsis. Andressa Freitas,José C Alves-Filho,Tatiana Victoni,Thomas Secher,Henrique P Lemoset al. Journal of Immunology, 2009, 182 (12), pp.7846-54. ⟨10.4049/jimmunol.0803039⟩ Article dans une revue hal-00404905v1
Crucial role of TNF receptors 1 and 2 in the control of polymicrobial sepsis. Thomas Secher,Virginie Vasseur,Didier Marc Poisson,Jane A Mitchell,Fernando Q Cunhaet al. Journal of Immunology, 2009, 182 (12), pp.7855-64. ⟨10.4049/jimmunol.0804008⟩ Article dans une revue hal-00404907v1
Toll-like receptor 2 is critical for induction of Reg3 beta expression and intestinal clearance of Yersinia pseudotuberculosis. R. Dessein,M. Gironella,Clémentine Vignal,L. Peyrin-Biroulet,H. Sokolet al. Gut, 2009, 58 (6), pp.771-6. ⟨10.1136/gut.2008.168443⟩ Article dans une revue istex hal-00404858v1
Radioresistant cells expressing TLR5 control the respiratory epithelium's innate immune responses to flagellin. Laure Janot,Jean-Claude Sirard,Thomas Secher,Nicolas Noulin,Lizette Ficket al. European Journal of Immunology, 2009, 39 (6), pp.1587-96. ⟨10.1002/eji.200838907⟩ Article dans une revue inserm-00385299v1
CD14 works with toll-like receptor 2 to contribute to recognition and control of Listeria monocytogenes infection. Laure Janot,Thomas Secher,David Torres,Isabelle Maillet,Josef Pfeilschifteret al. Journal of Infectious Diseases, 2008, 198 (1), pp.115-24. ⟨10.1086/588815⟩ Article dans une revue hal-00318570v1
Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury. Dieudonnée Togbe,Silvia Schnyder-Candrian,Bruno Schnyder,Emilie Doz,Nicolas Noulinet al. International Journal of Experimental Pathology, 2007, 88 (6), pp.387-91. ⟨10.1111/j.1365-2613.2007.00566.x⟩ Article dans une revue hal-00318537v1
Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. Jonathan Zalevsky,Thomas Secher,Sergei A Ezhevsky,Laure Janot,Paul M Steedet al. Journal of Immunology, 2007, 179 (3), pp.1872-83 Article dans une revue hal-00318488v1

Communication dans un congrès (2)

Mucosal administration of anti-bacterial antibody (Ab) provides long-term cross-protection against Pseudomonas aeruginosa respiratory infection Aubin Pitiot,Marion Ferreira,Christelle Parent,Chloé Boisseau,Mélanie Corteset al. Journées d'Animation Scientifique de la FéRI 2022 - FéRi Scientific Days 2022, Fédération de Recherche en Infectiologie (FéRI), Centre Val de Loire, Jul 2022, Joué-Lès-Tours, France Communication dans un congrès hal-03735460v1
A c-type lectin triggers immune surveillance by innate lymphoid cells for eradication of attaching-and-effacing bacteria Bruno Lamas,Nadine Waldschmitt,Sho Kitamoto,Thomas Secher,Vassiliki Zacharioudakiet al. 25. United European Gastroenterology: Week, Oct 2017, Barcelone, Spain Communication dans un congrès hal-02786603v1

Chapitre d'ouvrage (1)

Pulmonary Delivery of Antibody for the Treatment of Respiratory Diseases Thomas Secher,Nathalie Heuzé-Vourc’h Springer; AAPS. Respiratory Delivery of Biologics, Nucleic Acids, and Vaccines, 8, Springer International Publishing, pp.21-51, 2024, AAPS Introductions in the Pharmaceutical Sciences, ⟨10.1007/978-3-031-47567-2_2⟩ Chapitre d'ouvrage hal-04834340v1

Brevet (1)

Combination of inhaled antibodies and immunomodulatory agents for the treatment or prevention of respiratory infections Muriel Thomas,Nathalie Heuzé-Vourc’h,Thomas Secher France, Patent n° : FR2010296. 2020 Brevet hal-04292601v1

Pré-publication, Document de travail (1)

Pseudopaline-mediated zinc uptake by Pseudomonas aeruginosa determines several clinically relevant phenotypes and infection outcomes L Bosc,Thomas Secher,G Ball,Deborah Le Pennec,M Triboutet al. 2026 Pré-publication, Document de travail hal-05458361v1